Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 265

1.

Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale.

Clayton AH, Campbell BJ, Favit A, Yang Y, Moonsammy G, Piontek CM, Amsterdam JD.

J Clin Psychiatry. 2007 Dec;68(12):1860-6.

PMID:
18162016
2.

Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.

Feiger AD, Rickels K, Rynn MA, Zimbroff DL, Robinson DS.

J Clin Psychiatry. 2006 Sep;67(9):1354-61.

PMID:
17017821
3.

Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.

Robinson DS, Gilmor ML, Yang Y, Moonsammy G, Azzaro AJ, Oren DA, Campbell BJ.

Psychopharmacol Bull. 2007;40(3):15-28.

PMID:
18007565
6.

The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.

Robinson DS, Amsterdam JD.

J Affect Disord. 2008 Jan;105(1-3):15-23. Review.

PMID:
17568687
7.

Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder.

Delgado PL, Brannan SK, Mallinckrodt CH, Tran PV, McNamara RK, Wang F, Watkin JG, Detke MJ.

J Clin Psychiatry. 2005 Jun;66(6):686-92.

PMID:
15960560
8.

Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS).

Jang S, Jung S, Pae C, Kimberly BP, Craig Nelson J, Patkar AA.

J Affect Disord. 2013 Dec;151(3):854-9. doi: 10.1016/j.jad.2013.07.023.

PMID:
24021959
9.

Selegiline transdermal system: in the treatment of major depressive disorder.

Frampton JE, Plosker GL.

Drugs. 2007;67(2):257-65; discussion 266-7.

PMID:
17284087
10.

Transdermal selegiline.

Patkar AA, Pae CU, Zarzar M.

Drugs Today (Barc). 2007 Jun;43(6):361-77. Review.

PMID:
17612708
11.

Effects of testosterone on sexual function in men: results of a meta-analysis.

Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lenzi A.

Clin Endocrinol (Oxf). 2005 Oct;63(4):381-94. Review.

PMID:
16181230
12.
13.
14.

Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials.

Pae CU, Patkar AA, Jang S, Portland KB, Jung S, Nelson JC.

CNS Spectr. 2014 Aug;19(4):324-9. doi: 10.1017/S1092852913000655.

PMID:
24168807
15.

Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine.

Landén M, Högberg P, Thase ME.

J Clin Psychiatry. 2005 Jan;66(1):100-6.

PMID:
15669895
16.

A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction.

Clayton AH, Warnock JK, Kornstein SG, Pinkerton R, Sheldon-Keller A, McGarvey EL.

J Clin Psychiatry. 2004 Jan;65(1):62-7.

PMID:
14744170
17.

Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.

Jefferson JW, Rush AJ, Nelson JC, VanMeter SA, Krishen A, Hampton KD, Wightman DS, Modell JG.

J Clin Psychiatry. 2006 Jun;67(6):865-73.

PMID:
16848645
18.

Changes in sexual function during acute and six-month fluoxetine therapy: a prospective assessment.

Michelson D, Schmidt M, Lee J, Tepner R.

J Sex Marital Ther. 2001 May-Jun;27(3):289-302.

PMID:
11354934
19.
20.

Supplemental Content

Support Center